FASITIBANT

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C36H49Cl2N6O6S
Molecular Weight	764.782
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(C)=C2C=CC=C(OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@@H](N)CCC[N+](C)(C)C)C2=N1

InChI

InChIKey=FQVSDHOWSLEEKJ-LJAQVGFWSA-N

InChI=1S/C36H49Cl2N6O6S/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3/q+1/t29-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C36H49Cl2N6O6S
Molecular Weight	764.782
Charge	1
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	1 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17266207 | https://adisinsight.springer.com/drugs/800024707 | https://www.ncbi.nlm.nih.gov/pubmed/22638761 | https://www.ncbi.nlm.nih.gov/pubmed/19745108 | https://www.ncbi.nlm.nih.gov/pubmed/23973149 | https://clinicaltrials.gov/ct2/show/NCT02205814

Fasitibant (MEN-16132) is a non-peptide sulfonamide-containing bradykinin hB2 receptor antagonist. It inhibits pro-inflammatory response in vitro and alleviates inflammatory hyperalgesia in rodent models of osteoarthritis. Menarini Group was developing fasitibant for the treatment of osteoarthritis. Fasitibant development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
B2 bradykinin receptor 3 Target ID: P30411 Gene ID: 624.0 Gene Symbol: BDKRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17266207 \| https://www.ncbi.nlm.nih.gov/pubmed/16324696 \| https://www.ncbi.nlm.nih.gov/pubmed/21108627	Antagonist 2849		10.3 null [pKi]

PubMed

Title	Date	PubMed
Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E₂ release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes.	2012-08	22638761
Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of alpha,alpha-cycloalkylglycine sulfonamides.	2007-02-08	17266207

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Other

In Vitro Use Guide

Incubation of synoviocytes with BK induced a sustained production of PGE(2) and transient COX-2 gene expression that were prevented by pretreatment with fasitibant (1 μM, 30 min preincubation).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:47 GMT 2025`
Record UNII	0WL827Z7AE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FASITIBANT

Common Name

English

MEN-16132 FREE BASE

Preferred Name

English

FASITIBANT ION

Common Name

English

1-PIPERAZINEPENTANAMINIUM, .DELTA.-AMINO-4-((4-(((2,4-DICHLORO-3-(((2,4-DIMETHYL-8-QUINOLINYL)OXY)METHYL)PHENYL)SULFONYL)AMINO)TETRAHYDRO-2H-PYRAN-4-YL)CARBONYL)-N,N,N-TRIMETHYL-.EPSILON.-OXO-, (.DELTA.S)-

Common Name

English

Fasitibant [WHO-DD]

Common Name

English

FASITIBANT CATION

Common Name

English

Code System Code Type Description

DRUG BANK

DB15646